US 12,344,578 B2
Salt forms of bempedoic acid and methods for using the same
Richard Copp, Pinckney, MI (US); Mohamed Abdelnasser, New City, NY (US); Christopher M. Cimarusti, Clementon, NJ (US); and Chengxiang Liu, Cambridge, MA (US)
Assigned to Esperion Therapeutics, Inc., Ann Arbor, MI (US)
Appl. No. 17/620,885
Filed by Esperion Therapeutics, Inc., Ann Arbor, MI (US)
PCT Filed Jun. 19, 2020, PCT No. PCT/US2020/038624
§ 371(c)(1), (2) Date Dec. 20, 2021,
PCT Pub. No. WO2020/257573, PCT Pub. Date Dec. 24, 2020.
Claims priority of provisional application 62/864,873, filed on Jun. 21, 2019.
Prior Publication US 2023/0141635 A1, May 11, 2023
Int. Cl. C07C 51/04 (2006.01); C07C 59/285 (2006.01)
CPC C07C 51/04 (2013.01) [C07C 59/285 (2013.01); C07B 2200/13 (2013.01)] 18 Claims
 
1. A crystalline form of the compound of formula (V):

OG Complex Work Unit Chemistry
wherein the crystalline form of the compound of formula (V) is selected from the group consisting of a crystalline betaine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.2±0.2°, 13.5±0.2°, and 25.6±0.2°;
a crystalline calcium salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.9±0.2°, 9.1±0.2°, and 19.7±0.2°;
a crystalline calcium salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.0±0.2°, 6.8±0.2°, 8.5±0.2°, and 9.8±0.2°;
a crystalline diethylamine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 9.6±0.2°, 14.1±0.2°, and 19.8±0.2°;
a crystalline ethylenediamine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.8±0.2°, 16.2±0.2°, and 18.3±0.2°;
a crystalline isonicotinamide salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.4±0.2°, 18.8±0.2°, 20.1±0.2°, and 24.5±0.2°;
a crystalline potassium salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 5.7±0.2°, 7.3±0.2°, 9.6±0.2°, and 22.1±0.2°;
a crystalline L-lysine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.2±0.2°, 19.1±0.2°, and 21.9±0.2°;
a crystalline sodium salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.1±0.2°, 14.2±0.2°, 18.3±0.2°, and 24.5±0.2°;
a crystalline ammonium salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.1±0.2°, 14.3±0.2°, and 16.0±0.2°;
a crystalline piperazine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.7±0.2°, 15.7±0.2°, and 16.0±0.2°; and
a crystalline tromethamine salt characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.6±0.2°, 18.2±0.2°, 18.6±0.2°, and 19.8±0.2°.